jun 4, 2019: 11 a.m. - 12:15 p.m.
109AB, Level 100
In recent years, there%u2019s been a scarcity of high quality, revenue-generating biopharma assets. This dearth, coupled with larger pharma%u2019s growth requirements, has led to a significant run up in valuations of private and public biotech assets. As a result, organizations have been forced to adopt new and more advanced valuation techniques to appropriately evaluate acquisition targets. Representatives from the industry%u2019s most successful pharma/biotech organizations will share insights and best practices for capturing and analyzing the most relevant aspects in designing a comprehensive valuation for M&A and what challenges remain.